Search results
AbbVie completes acquisition of Celsius Therapeutics for $250m
Pharmaceutical Technology· 4 days agoAbbVie has acquired biotechnology company Celsius Therapeutics in a deal valued at $250m in cash....
ASCO24: AbbVie flexes early success of ADC pipeline in solid tumours
Clinical Trials Arena· 7 days agoAbbVie has announced positive data for its antibody-drug conjugate (ADC) therapies, Teliso-V,...
FDA issues complete response to AbbVie’s NDA for Parkinson’s drug
Pharmaceutical Technology· 6 days agoThe US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new...
AbbVie gains FDA approval for EPKINLY in follicular lymphoma
Pharmaceutical Technology· 5 days agoAbbVie has announced accelerated approval from the US Food and Drug Administration (FDA) for EPKINLY...
AbbVie expands its IBD prospects with $250M Celsius deal
BioPharma Dive· 5 days agoHunting another immunology drug, AbbVie announced Thursday it’s paying $250 million to acquire...
10 clinical trials to watch in the second half of 2024
BioPharma Dive· 20 hours agoStudy results are expected for two closely watched obesity drugs, while key tests await for a...
Coherus offloads Humira biosimilar Yusimry for $40m
Pharmaceutical Technology· 3 days agoCoherus Biosciences has divested Yusimry (adalimumab-aqvh), a biosimilar to AbbVie’s rheumatoid arthritis therapy Humira, to Hong Kong King-Friend...
Zealand hauls in $1B off obesity drug data; Curie.bio zeroes in on Series A’s
BioPharma Dive· 6 days agoZealand capitalized on a stock surge following the release of early study results. Elsewhere, U.S....
FDA Approves Skyrizi for Ulcerative Colitis
Verywell Health· 3 days agoThe FDA approves Skyrizi for the treatment of Ulcerative colitis. Here's what approval means and how the drug compares to other treatment options...
Nexalin’s deep brain stimulation add-on therapy alleviates depression
Medical Device Network· 5 days agoThe company’s deep brain stimulation device used in combination with medication is more effective in...